BiotechTube
Home/Pipeline/RUTI®

RUTI®

Tuberculosis (Latent/Drug-Resistant)

Phase 2 (based on prior studies; current development stage unclear)Active

Key Facts

Indication
Tuberculosis (Latent/Drug-Resistant)
Phase
Phase 2 (based on prior studies; current development stage unclear)
Status
Active
Company
Archivel Farma, Archivel Farma

About Archivel Farma

Archivel Farma is a dual-focus biotechnology company with a proprietary immunotherapeutic vaccine program for tuberculosis (RUTI®) and a growing CDMO services business. Its core assets include GMP-certified manufacturing facilities with Biosafety Level 3 (BSL-3) containment, enabling the production of sterile, freeze-dried biological products for itself and client partners. The company is advancing RUTI® into clinical studies for tuberculosis and exploring its application in oncology, such as bladder cancer, while simultaneously expanding its service offerings following a recent GMP certification renewal.

View full company profile

About Archivel Farma

Archivel Farma is a dual-focus biotechnology company with a proprietary immunotherapeutic vaccine program for tuberculosis (RUTI®) and a growing CDMO services business. Its core assets include GMP-certified manufacturing facilities with Biosafety Level 3 (BSL-3) containment, enabling the production of sterile, freeze-dried biological products for itself and client partners. The company is advancing RUTI® into clinical studies for tuberculosis and exploring its application in oncology, such as bladder cancer, while simultaneously expanding its service offerings following a recent GMP certification renewal.

View full company profile

Therapeutic Areas

Infectious DiseaseOncology